The largest database of trusted experimental protocols

84 protocols using genome wide human snp array 5

1

Genome-wide Genotyping and Imputation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Genome-wide genotyping in the Fenland cohort was performed in three subcohorts with use of the Affymetrix Genome-Wide Human SNP Array 5.0, the Affymetrix UK Biobank Axiom Array, or the Illumina CoreExome-24 v1 BeadChip, with imputation to the Haplotype Reference Consortium v1.1 (42 (link)), the 1000 Genomes Project (43 (link)), and the UK10K (44 (link)) reference panels. Samples from EPIC-Norfolk and UK Biobank were genotyped with the Affymetrix UK Biobank Axiom Array and imputed to the same reference panels.
+ Open protocol
+ Expand
2

KARE Cohort Genetic Analysis for T2D

Check if the same lab product or an alternative is used in the 5 most similar protocols
The KARE project began in 2007 with Ansung and Ansan regional cohorts representative of the general Korean population. The Affymetrix Genome-Wide Human SNP array 5.0 (Affymetrix Inc., Santa Clara, CA, USA) was used to analyze the genotype data from 10,038 participants. After quality control with a Hardy-Weinberg equilibrium p-value < 10-6 and genotype call rates less than 95%, and with the exclusion of SNPs with a minor allele frequency < 0.05, a total of 305,799 autosomal SNPs were utilized in this analysis. After eliminating participants with samples having low call rates (less than 96%), contaminated samples, gender inconsistency, serious concomitant illness, and cryptic relatedness, 8,842 samples (4,183 males and 4,659 females) were included in the analysis. Since our study focused on T2D, we selected only T2D patients and controls by excluding 3,863 samples using the T2D diagnostic criteria summarized in Table 1 [24 (link)]. Table 2 presents the demographic information of participants and differences in demographic variables between cases and controls.
Fig. 1 presents a principal component analysis plot that demonstrates the relationship between T2D and demographic variables. As can be seen in Fig. 1, demographic variation did not discriminate cases and controls well.
+ Open protocol
+ Expand
3

GWAS on Chronic Diseases in Korea

Check if the same lab product or an alternative is used in the 5 most similar protocols
For GWAS, we used Ansan-Anseong cohort data. These were for a study of a chronic diseases within Ansan city and Anseong rural areas in Korea. The dataset comprised men (8,842 people) between 40–69 years of age who had been residents of the region for at least 6 months [12 (link),13 (link)]. Our study was from the 3rd Ansan-Anseong cohort dataset version 2.1. The analyzed phenotypes were BF% unit and the covariates were set to be area, age and sex. The SNP dataset was implemented using Affymetrix Genome-wide Human SNP Array 5.0 (Affymetrix, Santa Clara, CA, USA). The mean call rate was 99.01%. The total number of SNPs was 352,228 and after quality control (minor allele frequency < 0.05, Hardy-Weinberg equilibrium p-value < 0.0001 and missing genotype rate > 0.05), 308,003 SNPs were left.
For transcript reads, we used transcript reads per million (TPM) data at the following website (http://www.proteinatlas.org). The Human Protein Atlas was released with protein profile data covering 48 different human tissues and organs, including adipocytes, the kidney and the liver [14 (link),15 (link)]. Among these organs, we used adipocyte’s transcript reads data. The TPM data of the Human Protein atlas is based on the reads per gene. Thus the gene length was pre-considered for the accurate reads estimation per gene.
+ Open protocol
+ Expand
4

Genotyping and QC for Childhood Obesity

Check if the same lab product or an alternative is used in the 5 most similar protocols
A childhood obesity study was genotyped using the Illumina Omni1-Quad BeadChip. Individuals were excluded based on the following criteria: genotyping call rate, sex inconsistency, heterozygosity, identity-by-state (IBS) value and any type of tumor. The results of this study have been previously reported52 (link). KARE samples were genotyped using Affymetrix Genome-Wide Human SNP array 5.0, and the Bayesian Robust Linear Modeling was processed using the Mahalanobis Distance (BRLMM) Genotyping Algorithm54 (link).
+ Open protocol
+ Expand
5

Genome-Wide Genotyping and Imputation

Check if the same lab product or an alternative is used in the 5 most similar protocols
All genotype data were approved and provided by the National Biobank of Korea and the Centers for Disease Control and Prevention, the Republic of Korea (no. 2019-022). Genotyping in the Ansung–Ansan cohort study was performed using the Affymetrix genome-wide human SNP array 5.0, and genotype imputation was performed using IMPUTE2; the 1000 genome projects of the East Asian ancestry sample was used as a reference panel. Genotyping in the HEXA study was performed using the Korean Chip designed by the Center for Genome Science at the Korean National Institutes of Health. The expected genotyping and quality-control information has been described previously in detail29 (link),30 (link).
+ Open protocol
+ Expand
6

Korean GWAS Data Curation and Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
For real data analysis, we chose a Korean GWAS data set collected since 2007 by The Korean Association REsource (KARE) project (Cho et al., 2009 (link)). In this project, all participants were recruited from either of two region-based cohorts (rural Ansung and urban Ansan). The total number of participants was 10,038 (5,018 from Ansung and 5,020 from Ansan), and they were all genotyped, using genomic DNA from peripheral blood, using the Affymetrix (Santa Clara, CA, United States) Genome-Wide Human SNP array 5.0, containing 500,568 SNPs. For quality control, we followed the same process used in a previous study (Oh et al., 2016 (link)). As a result, we finally obtained 8,842 individuals and 327,872 SNPs, and the processed data set was used in our real data analysis. The study was reviewed and approved by the Institutional Review Board of Seoul National University (IRB No. E1908/001-004).
+ Open protocol
+ Expand
7

Genotyping of the KARE Cohort

Check if the same lab product or an alternative is used in the 5 most similar protocols
The genotyping of the cohort population was previously described for the KARE study [16 (link)]. Most DNA samples were isolated from the peripheral blood of participants and genotyped using Affymetrix Genomewide Human SNP array 5.0 (Affymetrix, Inc., Santa Clara, CA, USA). The quality control steps of the genotypes have been described elsewhere [13 (link)]. Briefly, the calling of the genotyping was determined by Bayesian Robust Linear Modeling using the Mahalanobis Distance genotyping algorithm [17 (link)]. Consequently, 352,227 SNPs had a missing genotype call rate below 0.1, a minor allele frequency greater than 0.01, and no deviation from Hardy-Weinberg equilibrium (p > 1 × 10-6). Additionally, the previous GWAS reported no population stratification between the Anseong and Ansan cohorts [13 (link)].
+ Open protocol
+ Expand
8

Genome-Wide Genotyping and Imputation

Check if the same lab product or an alternative is used in the 5 most similar protocols
All of the 10,004 KARE study samples were genotyped using the Affymetrix Genome-Wide Human SNP array 5.0. After quality control, 8,842 subjects and 352,228 SNPs remained for analyses. For in silico replication, 4,302 individuals from the HEXA cohort were genotyped using the Affymetrix Genome-Wide Human SNP array 6.0. After quality control, 3,703 samples and 646,062 SNPs remained. Genotype calling methods and quality control criteria for samples and SNPs of both cohorts have been previously described [11 (link),19 (link)].
SNP imputation was conducted using the IMPUTE program [20 (link)] based on International HapMap (phase 2, release 22, NCBI build 36 and dbSNP build 126; http://hapmap.ncbi.nlm.nih.gov/) data from JPT and CHB populations. We used 1,573,409 SNPs for the KARE study and 1,984,393 SNPs for the HEXA cohort after excluding imputed SNPs of unsatisfactory quality for genetic analyses [19 (link)].
The results for replication stage 2 were generated from 356 individuals from the Ehime study using the Illumina Human Omni 2.5-8 BeadChip and 485 individuals from the Amagasaki study using the Illumina HumanHap 550 k Quad BeadChip.
+ Open protocol
+ Expand
9

Genome-Wide Association Study of Korean Women

Check if the same lab product or an alternative is used in the 5 most similar protocols
The samples and genotype data used in this study have been previously described (35) (link). Briefly, through the Korea Association Resource (KARE) project, a total of 10,038 participants were recruited from Ansan and Ansung population-based cohorts, aged 40 to 69. 10,004 samples were genotyped, using the Affymetrix Genome-Wide Human SNP array 5.0. A total of 352,228 markers in 8,842 individuals were obtained, after removing samples and markers that failed a quality control test (35) (link). We studied 4,659 women samples of them, and used the P values of the imputed genotypes (1,827,004 SNPs). SNP imputation has also been described (35) (link). Briefly, using the IMPUTE program (36) (link) the KARE genotypes were supplemented, by imputing SNP genotypes based on 90 individuals from the unrelated Chinese in Beijing (CHB), and Japanese in Tokyo (JPT) founders in HapMap.
SOS was tested for association by linear regression analysis with dominant, additive, and recessive models, after adjusting for age and height as covariates, using PLINK.
+ Open protocol
+ Expand
10

Genetic Factors in Cardiovascular Disease

Check if the same lab product or an alternative is used in the 5 most similar protocols
The genotypes were obtained using Affymetrix Genome-Wide Human SNP array 5.0 (Affymetrix Inc., Santa Clara, CA, USA), which contains 500,568 SNPs constructed by the Korea Biobank Array. To examine the relationship between genetic polymorphism and CVD, we selected the significant SNPs by p-values.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!